TB-500 Human Studies: What the Evidence Actually Shows
Animal research on TB-500 is real, and so is some human trial data. But that human data was run on a different, full-length molecule. Here is the honest breakdown of what has been shown about the TB-500 fragment itself.
Human trials, fragment
None published
Parent molecule, human
Early-phase trials
Animal evidence
Moderate
Mechanism
Plausible
Two molecules, two research threads
The whole evidence picture turns on one distinction that is easy to miss when skimming.
TB-500 (the fragment)
A synthetic peptide built around the actin-binding region of Thymosin Beta-4. This is what is sold in the research-peptide market. Its direct evidence is animal research, not human trials.
Thymosin Beta-4 (the parent)
The natural, full-length 43-amino-acid peptide found in nearly all human cells. The early-phase human trials that exist were run on this molecule, in a separate research program.
Why it matters: claims about TB-500 in humans are usually extrapolated from two places, animal data on the fragment and human data on the different full-length molecule. Neither is direct human evidence for the fragment as sold, and conflating them overstates what has actually been shown.
What has been studied, and how strong it is
Read top to bottom: the strongest human data sits on the parent molecule, the fragment-specific data is animal, and the direct human trial is the gap.
-
Human, parent molecule
Thymosin Beta-4 early-phase trials
Early-phase human clinical trials have explored full-length Thymosin Beta-4 for chronic wound healing, such as diabetic foot and pressure ulcers, and for dry eye conditions. Real human data, but collected on a different molecule than the fragment sold as TB-500.
-
Animal, the fragment
Preclinical studies on TB-500 itself
The direct evidence for the fragment is animal-based, mostly rodents, examining wound healing, soft-tissue and muscle repair, and recovery of cardiac tissue after injury. This is the primary evidence source specific to TB-500, since dedicated human trials on it do not exist.
-
Mechanism
Actin regulation and angiogenesis
Both the parent and the fragment are thought to act partly through actin regulation, supporting cell migration to injury sites, and through promoting angiogenesis, the formation of new blood vessels. Biologically reasonable and consistent with the animal work, but plausibility is a hypothesis, not confirmation in humans.
-
The gap
No controlled human trials on the fragment
What is missing is specific: dedicated, peer-reviewed, randomized controlled human trials conducted on the TB-500 fragment itself. Until that exists, human-effect claims should be read as extrapolated, not clinically confirmed for the fragment.
Where TB-500 stands in 2026
Prescription compounding
Under the October 2026 draft HHS policy, licensed 503A pharmacies can compound TB-500 acetate by injection, by prescription, single-ingredient and fully tested.
Not FDA-approved
The FDA advisory panel voted to recommend it in July 2026, but it is not on the 503A list yet and no final rule exists. The policy is a draft and nonbinding.
Research versions
TB-500 sold as a research chemical is for laboratory use only, not for human consumption, and is not covered by the HHS policy.
The full picture: FDA peptide status tracker and what changed in 2026.
Bloodwork worth tracking
There is no blood marker specific to TB-500, so the goal is a general safety baseline.
- Comprehensive metabolic panel for kidney, liver and electrolyte baseline
- CBC for a general blood-count baseline
- A symptom and recovery log, since there is no objective marker that tracks the compound itself
What each test covers: the peptide bloodwork guide.
Frequently asked questions
Has TB-500 been tested in human clinical trials?
The TB-500 fragment itself has not been the subject of dedicated, published human clinical trials. The human trial work that exists was run on Thymosin Beta-4, the full-length parent molecule TB-500 is derived from, in a separate research program covering areas like chronic wound healing and dry eye. That is not the same as testing the shorter fragment most people mean by TB-500.
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the natural, full-length 43-amino-acid peptide found in nearly all human cells. TB-500 is a synthetic peptide built around its actin-binding region. They are related but not identical, and the distinction matters because the early human trials were on the full-length molecule, while the animal data is on the fragment. What is sold as TB-500 also varies by seller, so a certificate of analysis matters.
What does the animal research on TB-500 show?
The preclinical base specific to the fragment is animal research, mostly in rodents, looking at wound healing, soft-tissue and muscle repair, and recovery of cardiac tissue after injury. These studies support the proposed actin-regulation and angiogenesis mechanisms, but animal results are a starting hypothesis, not proof the fragment behaves the same way in people.
Is TB-500 FDA-approved or legal to buy?
TB-500 is not FDA-approved. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend it for the 503A compounding list, and in October 2026 HHS announced a draft enforcement-discretion policy that lets licensed 503A pharmacies compound TB-500 acetate by injection, by prescription, under strict testing and labeling rules. That is not FDA approval, it is a draft and nonbinding, and it does not cover research-chemical sellers, which market TB-500 for laboratory use only.
What would strengthen the evidence case for TB-500?
Dedicated, peer-reviewed, randomized controlled human trials run on the TB-500 fragment itself, rather than on the full-length Thymosin Beta-4 molecule. Until trials test the fragment directly, claims about its effects in humans stay extrapolated from animal data on the fragment and human data on a related but distinct molecule.
Track your protocol with the evidence in view
Log injections, recovery and bloodwork in one place, and score where a compound fits your stack. Free.
Sources
- Thymosin Beta-4 early-phase human clinical trials in wound healing and dry eye (full-length parent molecule), reviewed in the peptide literature. ClinicalTrials.gov: thymosin beta-4
- Preclinical (animal) research on the TB-500 fragment and thymosin beta-4 in tissue repair and angiogenesis. PMC: thymosin beta-4 tissue repair
- HHS draft enforcement-discretion policy on 503A peptide compounding (TB-500 acetate, injection), Federal Register Oct 30, 2026, FR Doc. 2026-22192. federalregister.gov
- FDA Pharmacy Compounding Advisory Committee vote, July 24, 2026. AJMC summary
This content is for informational purposes only and is not medical advice. TB-500 is not FDA-approved in the United States. The human trial data referenced was collected on full-length Thymosin Beta-4, not the TB-500 fragment. Research-grade TB-500 is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.